КЛИНИКО-ЭКОНОМИЧЕСКИЙ АНАЛИЗ ПРИМЕНЕНИЯ ПРОТИВООПУХОЛЕВОГО ЛЕКАРСТВЕННОГО ПРЕПАРАТА ЭРИБУЛИН (ХАЛАВЕН®) ДЛЯ ЛЕЧЕНИЯ БОЛЬНЫХ С МЕТАСТАТИЧЕСКИМ РАКОМ МОЛОЧНОЙ ЖЕЛЕЗЫ

Breast cancer is the most common cause of death from cancer among women in Russia. More than half of patients have metastases at diagnosis. Chemotherapy is an important component of combined modality treatment for breast cancer. The budget impact analysis of expenses for the use of eribulina demonstrated that its inclusion in the «List of Essential Drugs» greatly expand the possibilities of treatment for metastatic breast cancer without causing significant additional burden on the health budget of the Russian Federation.Рак молочной железы лидирует в структуре онкологической смертности женского населения России. Более половины пациенток имеют метастазы на момент установки диагноза. Химиотерапия является важным компонентом комплексного или комбинированного лечения рака молочной железы. Проведенный анализ влияния на бюджет затрат на использование эрибулина продемонстрировал, что его включение в «Перечень жизненно необходимых и важнейших лекарственных препаратов» существенно расширит возможности лечения метастатического рака молочной железы, не приводя к значимой дополнительной нагрузке на бюджет здравоохранения Российской Федерации

COST-EFFECTIVENESS AND COST-UTILITY OF GENOTHERAPEUTIC DRUG NEOVASCULGEN IN TREATMENT OF CHRONIC LOWER LIMB ISCHEMIA

Pl-VEGF165 (Neovasculgen) is a new genotherapeutic drug for treatment of chronic lower limb ischemia.  It is registered in Russia and underwent effectiveness assessment in clinical trial. Objective of this study is to report results of the economical modeling study to compare long-term effectiveness and costs of the treatment. The comparison show that the treatment with this drug allows to decrease number of amputations by 6.5 fold and increase quality adjusted length of life by 2.6 QALYs. Summary  costs were lower with new drug by 574 thousand rubles with lifelong modeling and by 353 thousand rubles in first 5 years

CLINICAL ECONOMIC ANALYSIS OF USING ERIBULIN (HALAVEN®) FOR TREATMENT OF PATIENTS WITH METASTATIC BREAST CANCER

Breast cancer is the most common cause of death from cancer among women in Russia. More than half of patients have metastases at diagnosis. Chemotherapy is an important component of combined modality treatment for breast cancer. The budget impact analysis of expenses for the use of eribulina demonstrated that its inclusion in the «List of Essential Drugs» greatly expand the possibilities of treatment for metastatic breast cancer without causing significant additional burden on the health budget of the Russian Federation